NCT00145171View on ClinicalTrials.gov

A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.

PHASE3CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

February 28, 2001

Study Completion Date

August 31, 2002

Conditions
Parkinson Disease
Interventions
DRUG

apomorphine HCl injection

Sponsors
All Listed Sponsors
lead

Mylan Bertek Pharmaceuticals

INDUSTRY